We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+6.87%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$9.54B
AUM Growth
+$55.8M
Cap. Flow
-$1.48B
Cap. Flow %
-15.48%
Top 10 Hldgs %
82.65%
Holding
142
New
10
Increased
13
Reduced
15
Closed
7

Top Buys

Rank Stock Value
1
NTLA icon
Intellia Therapeutics
NTLA
+$28.3M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$10.1M
3
MRUS
Merus
MRUS
+$9.82M
4
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$6.94M
5
ALDR
Alder Biopharmaceuticals
ALDR
+$5.88M

Top Sells

Rank Stock Value
1
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$274M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.9M
3
OMER icon
Omeros
OMER
+$11.5M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$9.52M
5
IMGN
Immunogen Inc
IMGN
+$9.01M

Sector Composition

Rank Sector Weight
1 Healthcare 80.73%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$25.3B
$1.88B 19.7%
23,498,697
+237
+0% +$18.4K
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$1.75B 18.32%
43,238,967
+3,700
+0% +$141K
ABBV icon
3
AbbVie
ABBV
$472B
$890M 9.33%
14,373,538
– –
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$4.45B
$796M 8.34%
24,516,738
+302,900
+1% +$10.1M
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$764M 8.01%
6,543,295
+696
+0% +$98.8K
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$12B
$374M 3.92%
4,806,483
– –
GHDX
7
DELISTED
Genomic Health, Inc.
GHDX
$354M 3.71%
13,668,866
+9,034
+0.1% +$240K
DBVT
8
DBV Technologies
DBVT
$797M
$180M 1.88%
550,956
– –
ACOR
9
DELISTED
Acorda Therapeutics
ACOR
$93.4M 0.98%
30,509
– –
CERS icon
10
Cerus
CERS
$577M
$84.6M 0.89%
13,553,275
– –
ONCE
11
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$67.4M 0.71%
1,318,341
+55,959
+4% +$2.39M
BLCM
12
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$63.1M 0.66%
486,565
– –
ONC
13
BeOne Medicines Ltd
ONC
$34.1B
$57M 0.6%
1,912,680
– –
HRTX icon
14
Heron Therapeutics
HRTX
$92.5M
$51.6M 0.54%
2,857,250
-50,534
-2% -$987K
NGNE icon
15
Neurogene
NGNE
$647M
$51.3M 0.54%
387,624
– –
NVTA
16
DELISTED
Invitae Corporation
NVTA
$48.4M 0.51%
6,554,967
– –
BCRX icon
17
BioCryst Pharmaceuticals
BCRX
$2.44B
$42.6M 0.45%
15,010,534
– –
NBIX icon
18
Neurocrine Biosciences
NBIX
$18.3B
$40.7M 0.43%
895,422
– –
ARAV
19
DELISTED
Aravive, Inc. Common Stock
ARAV
$30.1M 0.32%
453,900
-79,360
-15% -$4.51M
AAAP
20
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$25.2M 0.26%
833,089
+218,056
+35% +$6.94M
XNPT
21
DELISTED
XENOPORT, INC.
XNPT
$24.5M 0.26%
3,475,672
– –
ITCI
22
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$23.6M 0.25%
609,166
– –
SGMO
23
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$23.5M 0.25%
4,055,876
– –
NTLA icon
24
Intellia Therapeutics
NTLA
$1.48B
$22.7M 0.24%
+1,062,120
New +$28.3M
EXEL icon
25
Exelixis
EXEL
$14.1B
$20.1M 0.21%
2,580,000
– –
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2016 Portfolio in Review

As of Q2 2016, Baker Bros. Advisors held 142 positions worth $9.54B, up 0.59% from $9.48B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Baker Bros. Advisors withdrew a net $1.48B in Q2 2016, closing 7 positions and reducing 15 holdings. Its most notable exit was ANACOR PHARMACEUTICALS INC COM, an estimated $274M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 77% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in Intellia Therapeutics worth $22.7M.

  • Baker Bros. Advisors's largest Q2 2016 buy was Intellia Therapeutics: 1,062,120 shares worth $22.7M.
  • Baker Bros. Advisors added most to Acadia Pharmaceuticals in Q2 2016, an estimated $10.1M increase.
  • Baker Bros. Advisors's biggest Q2 2016 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $15.9M.
  • Baker Bros. Advisors fully exited ANACOR PHARMACEUTICALS INC COM in Q2 2016, selling an estimated $274M.
  • Baker Bros. Advisors's ten largest holdings make up 83% of its $9.54B portfolio in Q2 2016.
  • Baker Bros. Advisors opened 10 new positions and closed 7 in Q2 2016.
  • Baker Bros. Advisors's portfolio value rose 0.59% quarter-over-quarter to $9.54B.

Based on Baker Bros. Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.